ProShare Advisors LLC Increases Position in DaVita Inc. (NYSE:DVA)

ProShare Advisors LLC lifted its position in shares of DaVita Inc. (NYSE:DVA) by 3.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,537 shares of the company’s stock after purchasing an additional 268 shares during the period. ProShare Advisors LLC’s holdings in DaVita were worth $1,044,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of DVA. Franklin Resources Inc. grew its position in shares of DaVita by 42.0% in the 4th quarter. Franklin Resources Inc. now owns 7,866 shares of the company’s stock valued at $824,000 after buying an additional 2,325 shares during the last quarter. Advisory Services Network LLC purchased a new stake in DaVita in the fourth quarter valued at approximately $385,000. Treasurer of the State of North Carolina boosted its holdings in shares of DaVita by 1.0% in the fourth quarter. Treasurer of the State of North Carolina now owns 24,737 shares of the company’s stock valued at $2,591,000 after acquiring an additional 234 shares during the period. TFO Wealth Partners LLC grew its position in shares of DaVita by 56,133.3% during the fourth quarter. TFO Wealth Partners LLC now owns 1,687 shares of the company’s stock worth $177,000 after acquiring an additional 1,684 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of DaVita by 4.2% in the 4th quarter. California State Teachers Retirement System now owns 87,217 shares of the company’s stock valued at $9,137,000 after acquiring an additional 3,543 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Activity

In related news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares in the company, valued at approximately $36,299,008.35. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 in the last 90 days. 2.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on DVA. TD Cowen increased their price target on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Truist Financial raised their price target on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Tuesday, August 20th. UBS Group upped their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Finally, Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus target price of $157.00.

DaVita Price Performance

Shares of DVA opened at $163.08 on Friday. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The stock’s 50 day moving average is $150.14 and its two-hundred day moving average is $142.11. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $166.04. The firm has a market capitalization of $14.30 billion, a PE ratio of 18.53, a P/E/G ratio of 0.93 and a beta of 0.87.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.08 earnings per share. Research analysts anticipate that DaVita Inc. will post 9.99 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.